Insulin glulisine
Lua error in package.lua at line 80: module 'strict' not found.
| Clinical data | |
|---|---|
| Trade names | Apidra |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607033 |
| Pregnancy category |
|
| Legal status | |
| Routes of administration |
Subcutaneous |
| Identifiers | |
| CAS Number | 207748-29-6  |
| ATC code | A10AB06 (WHO) |
| DrugBank | DB01309  |
| UNII | 7XIY785AZD |
| KEGG | D04540 |
| Chemical data | |
| Formula | C258H384N64O78S6 |
| Molecular mass | 5823 g/mol |
| (what is this?) (verify) |
|
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[1] It was developed by Sanofi-Aventis and sold under the trade name Apidra.[2] When injected subcutaneously, it appears in the blood earlier than human insulin.[3] When used as a meal time insulin, the dose is given within 15 minutes before a meal or within 20 minutes after starting a meal.[4] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[5]
References
- ↑ DailyMed: apidra (insulin glulisine) injection, solution
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Drugs.com: Insulin Glulisine
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
External links
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- Pharmacology articles needing expert attention
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Articles without InChI source
- Insulin therapies
- Gastrointestinal system drug stubs
